Blindness Clinical Trial
Official title:
Wayfinding Information Access System for People With Vision Loss
Verified date | February 2014 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The purpose of the project is to find out what kinds of information are most useful to visually impaired people when they are moving around indoors and what kinds of controls will make it easy for visually impaired people to control a device to help orient them to an unfamiliar indoor space.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be blind with no better vision than light perception and must be able to do 3 hours of walking (with many breaks) Exclusion Criteria: |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Atlanta VA Medical and Rehab Center, Decatur | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Percent (Prototype / Baseline) Time | The outcome measure for each subject is the mean of the (Prototype Time / Baseline Time) across 12 trials. The outcome measure for the experiment is the mean of 24 individual subject mean scores. This mean outcome measure is expressed as a percentage of the mean Baseline Time, where improved performance is represented by a percentage that is less than 100 percent of the Baseline Time. The lower the percentage, the better the performance improvement. | 2 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02393118 -
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
|
N/A | |
Terminated |
NCT00262509 -
Emergency Egress and Information System for Persons With Vision Loss
|
N/A | |
Terminated |
NCT00691444 -
Blind Child Melatonin Treatment Study
|
N/A | |
Recruiting |
NCT06237829 -
Testing Tactile Aids With Blind Subjects
|
N/A | |
Completed |
NCT01488786 -
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
|
N/A | |
Completed |
NCT02643238 -
Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation
|
N/A | |
Recruiting |
NCT00403143 -
Do Blue-Blocking Lenses Block Blue Colour From Our Lives?
|
N/A | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT04725760 -
Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population
|
N/A | |
Recruiting |
NCT02983370 -
Development of a Cortical Visual Neuroprosthesis for the Blind
|
N/A | |
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
Completed |
NCT01109576 -
Workshops for Veterans With Vision and Hearing Loss
|
Phase 0 | |
Completed |
NCT00920231 -
Computer Vision System for the Blind Veteran
|
Phase 1 | |
Terminated |
NCT00795236 -
Melatonin Studies of Totally Blind Children
|
N/A | |
Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
Enrolling by invitation |
NCT06364605 -
MySpace: the Role of Vision in Representing Space
|
N/A | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05806684 -
Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 |